Skip to main content
Top
Published in: Nuclear Medicine and Molecular Imaging 3/2013

01-09-2013 | Case Report

Myocardial Fibrosis in Hypertrophic Cardiomyopathy Demonstrated by Integrated Cardiac F-18 FDG PET/MR

Authors: Eun-jung Kong, Sang-hee Lee, Ihn-ho Cho

Published in: Nuclear Medicine and Molecular Imaging | Issue 3/2013

Login to get access

Abstract

Hypertrophic cardiomyopathy (HCM) is a common condition defined as a diffuse or segmental left ventricular (LV) hypertrophy with a nondilated and hyperdynamic chamber as well as cardiac arrhythmias. Cardiac MR (CMR) imaging is a key modality for evaluation of HCM. In addition to the assessment of LV wall thickness, LV function and aortic flow, CMR is capable of estimation of late gadolinium enhancement (LGE) in affected myocardium which has been shown to have a direct correlation with incidence and severity of arrhythmias in HCM. In patients with HCM, LGE on CMR is presumed to represent intramyocardial fibrosis. Meanwhile, F-18 FDG myocardial PET has been sporadically studied in HCM, mostly for evaluation of the metabolic status of a hypertrophic myocardial segment, especially after interventions or to demonstrate partial myocardial fibrosis. We presented here the case of a 25-year-old male patient referred for simultaneous F-18 FDG cardiac PET/MR for the evaluation of septal hypertrophy. The PET/MR revealed myocardial fibrosis in the septum associated with FDG-defect and LGE.
Literature
2.
go back to reference Kelley-Hedgepeth A, Maron MS. Imaging techniques in the evaluation and management of hypertrophic cardiomyopathy. Curr Heart Fail Rep. 2009;6:135–41.PubMedCrossRef Kelley-Hedgepeth A, Maron MS. Imaging techniques in the evaluation and management of hypertrophic cardiomyopathy. Curr Heart Fail Rep. 2009;6:135–41.PubMedCrossRef
3.
go back to reference Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405–12.PubMedCrossRef Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405–12.PubMedCrossRef
4.
go back to reference Jackson E, Bellenger N, Seddon M, Harden S, Peebles C. Ischaemic and non-ischaemic cardiomyopathies–cardiac MRI appearances with delayed enhancement. Clin Radiol. 2007;62:395–403.PubMedCrossRef Jackson E, Bellenger N, Seddon M, Harden S, Peebles C. Ischaemic and non-ischaemic cardiomyopathies–cardiac MRI appearances with delayed enhancement. Clin Radiol. 2007;62:395–403.PubMedCrossRef
5.
go back to reference Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3:51–8.PubMedCrossRef Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3:51–8.PubMedCrossRef
6.
go back to reference Bravo PE, Pinheiro A, Higuchi T, Rischpler C, Merrill J, Santaularia-Tomas M, et al. PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy. J Nucl Med. 2012;53:407–14.PubMedCrossRef Bravo PE, Pinheiro A, Higuchi T, Rischpler C, Merrill J, Santaularia-Tomas M, et al. PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy. J Nucl Med. 2012;53:407–14.PubMedCrossRef
7.
go back to reference Funabashi N, Nakagawa K, Komuro I. Partial myocardial fibrosis in hypertrophic cardiomyopathy demonstrated by 18F-fluoro-deoxyglucose positron emission tomography and multislice computed tomography. Int J Cardiol. 2006;107:284–6.PubMedCrossRef Funabashi N, Nakagawa K, Komuro I. Partial myocardial fibrosis in hypertrophic cardiomyopathy demonstrated by 18F-fluoro-deoxyglucose positron emission tomography and multislice computed tomography. Int J Cardiol. 2006;107:284–6.PubMedCrossRef
8.
go back to reference Kuhn H, Gietzen FH, Schafers M, Freick M, Gockel B, Strunk-Muller C, et al. Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion. Eur Heart J. 1999;20:1808–17.PubMedCrossRef Kuhn H, Gietzen FH, Schafers M, Freick M, Gockel B, Strunk-Muller C, et al. Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion. Eur Heart J. 1999;20:1808–17.PubMedCrossRef
9.
go back to reference Maron MS, Olivotto I, Maron BJ, Prasad SK, Cecchi F, Udelson JE, et al. The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54:866–75.PubMedCrossRef Maron MS, Olivotto I, Maron BJ, Prasad SK, Cecchi F, Udelson JE, et al. The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54:866–75.PubMedCrossRef
10.
go back to reference Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51:1369–74.PubMedCrossRef Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51:1369–74.PubMedCrossRef
11.
go back to reference Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail. 2008;1:184–91.PubMedCrossRef Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail. 2008;1:184–91.PubMedCrossRef
12.
go back to reference Kuribayashi T, Roberts WC. Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. Am J Cardiol. 1992;70:1333–40.PubMedCrossRef Kuribayashi T, Roberts WC. Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. Am J Cardiol. 1992;70:1333–40.PubMedCrossRef
13.
go back to reference Kim RJ, Judd RM. Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: in vivo imaging of the pathologic substrate for premature cardiac death? J Am Coll Cardiol. 2003;41:1568–72.PubMedCrossRef Kim RJ, Judd RM. Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: in vivo imaging of the pathologic substrate for premature cardiac death? J Am Coll Cardiol. 2003;41:1568–72.PubMedCrossRef
14.
go back to reference Tadamura E, Tamaki N, Matsumori A, Magata Y, Yonekura Y, Nohara R, et al. Myocardial metabolic changes in hypertrophic cardiomyopathy. J Nucl Med. 1996;37:572–7.PubMed Tadamura E, Tamaki N, Matsumori A, Magata Y, Yonekura Y, Nohara R, et al. Myocardial metabolic changes in hypertrophic cardiomyopathy. J Nucl Med. 1996;37:572–7.PubMed
15.
go back to reference Shiba N, Kagaya Y, Ishide N, Otani H, Takeyama D, Yamane Y, et al. Heterogeneity of myocardial fluoro-18 2-deoxyglucose uptake in patients with apical hypertrophic cardiomyopathy. Jpn Circ J. 1997;61:223–30.PubMedCrossRef Shiba N, Kagaya Y, Ishide N, Otani H, Takeyama D, Yamane Y, et al. Heterogeneity of myocardial fluoro-18 2-deoxyglucose uptake in patients with apical hypertrophic cardiomyopathy. Jpn Circ J. 1997;61:223–30.PubMedCrossRef
16.
go back to reference Wang L, Yan C, Zhao S, Fang W. Comparison of 99mTc-MIBI SPECT/18F-FDG PET imaging and cardiac magnetic resonance imaging in patients with idiopathic dilated cardiomyopathy: assessment of cardiac function and myocardial injury. Clin Nucl Med. 2012;37:1163–9.PubMedCrossRef Wang L, Yan C, Zhao S, Fang W. Comparison of 99mTc-MIBI SPECT/18F-FDG PET imaging and cardiac magnetic resonance imaging in patients with idiopathic dilated cardiomyopathy: assessment of cardiac function and myocardial injury. Clin Nucl Med. 2012;37:1163–9.PubMedCrossRef
17.
go back to reference Handa N, Magata Y, Mukai T, Nishina T, Konishi J, Komeda M. Quantitative FDG-uptake by positron emission tomography in progressive hypertrophy of rat hearts in vivo. Ann Nucl Med. 2007;21:569–76.PubMedCrossRef Handa N, Magata Y, Mukai T, Nishina T, Konishi J, Komeda M. Quantitative FDG-uptake by positron emission tomography in progressive hypertrophy of rat hearts in vivo. Ann Nucl Med. 2007;21:569–76.PubMedCrossRef
Metadata
Title
Myocardial Fibrosis in Hypertrophic Cardiomyopathy Demonstrated by Integrated Cardiac F-18 FDG PET/MR
Authors
Eun-jung Kong
Sang-hee Lee
Ihn-ho Cho
Publication date
01-09-2013
Publisher
Springer Berlin Heidelberg
Published in
Nuclear Medicine and Molecular Imaging / Issue 3/2013
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-013-0201-0

Other articles of this Issue 3/2013

Nuclear Medicine and Molecular Imaging 3/2013 Go to the issue